In medical news:

Regeneron Pharmaceuticals and partner Teva Pharmaceutical Industries said the U.S. health regulator placed a clinical hold on a study testing their pain treatment, dealing another blow to companies looking to develop tamper resistant opioids. According to Reuters, Monday’s announcement suggests fasinumab will be plagued by the same limitations as other drugs in its class, including heightened scrutiny, repeated delays, and labeling restrictions.

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *